Liver cancer treatment company Sirtex Medical last week announced its dose sales for the fourth quarter of 2012. Consistent with the strong growth reported in the third quarter, dose sales rose 26% in the fourth quarter. For the full year, dose sales were up 23% (compared with a 19% increase in the previous year).
US quarterly dose sales grew 31%—lower than the 47% increase reported in the third quarter, but still an excellent result. Europe reported 11% growth for the quarter, a decent recovery from the sluggish numbers of earlier in the year.